PURPOSE: The volume treated with postoperative radiation therapy (PORT) is a mediator of toxicity, and reduced volumes result in improved quality of life (QOL). In this phase II trial, treatment volumes were reduced by omitting PORT to the pathologically negative (PN0) neck in patients with primary head and neck squamous cell carcinoma. METHODS: Patients with head and neck squamous cell carcinoma who underwent surgical resection and neck dissection with a PN0 neck and high-risk features mandating PORT to the primary and/or involved neck were eligible. The primary end point was greater than 90% disease control in the unirradiated neck. QOL was evaluated using the MD Anderson Dysphagia Inventory and the University of Michigan patient-reported xerostomia questionnaire. RESULTS: Seventy-three patients were enrolled, and 72 were evaluable. Median age was 56 years (range, 31 to 81 years); 58 patients were male, and 47 (65%) had a smoking history. Sites included oral cavity (n = 14), oropharynx (n = 37), hypopharynx (n = 4), larynx (n = 16), and unknown primary tumor (n = 1). According to the American Joint Committee on Cancer Staging Manual (7th edition), 67 patients (93%) had stage III/IV disease, and 71% of tumors involved or crossed midline. No patient had contralateral neck PORT. In 17 patients (24%), only the primary site was treated. At a median follow-up of 53 months, two patients experienced treatment failure of the PN0 unirradiated neck; they also experienced treatment failure locally. Unirradiated neck control was 97% (95% CI, 93.4% to 100.0%). Five-year rates of local control, regional control, progression-free survival, and overall survival were 84%, 93%, 60%, and 64%, respectively. QOL measures were not significantly different from baseline at 12 and 24 months post-PORT (P > .05). CONCLUSION: Eliminating PORT to the PN0 neck resulted in excellent control rates in the unirradiated neck without long-term adverse effects on global QOL.
PURPOSE: The volume treated with postoperative radiation therapy (PORT) is a mediator of toxicity, and reduced volumes result in improved quality of life (QOL). In this phase II trial, treatment volumes were reduced by omitting PORT to the pathologically negative (PN0) neck in patients with primary head and neck squamous cell carcinoma. METHODS:Patients with head and neck squamous cell carcinoma who underwent surgical resection and neck dissection with a PN0 neck and high-risk features mandating PORT to the primary and/or involved neck were eligible. The primary end point was greater than 90% disease control in the unirradiated neck. QOL was evaluated using the MD Anderson Dysphagia Inventory and the University of Michigan patient-reported xerostomia questionnaire. RESULTS: Seventy-three patients were enrolled, and 72 were evaluable. Median age was 56 years (range, 31 to 81 years); 58 patients were male, and 47 (65%) had a smoking history. Sites included oral cavity (n = 14), oropharynx (n = 37), hypopharynx (n = 4), larynx (n = 16), and unknown primary tumor (n = 1). According to the American Joint Committee on Cancer Staging Manual (7th edition), 67 patients (93%) had stage III/IV disease, and 71% of tumors involved or crossed midline. No patient had contralateral neck PORT. In 17 patients (24%), only the primary site was treated. At a median follow-up of 53 months, two patients experienced treatment failure of the PN0 unirradiated neck; they also experienced treatment failure locally. Unirradiated neck control was 97% (95% CI, 93.4% to 100.0%). Five-year rates of local control, regional control, progression-free survival, and overall survival were 84%, 93%, 60%, and 64%, respectively. QOL measures were not significantly different from baseline at 12 and 24 months post-PORT (P > .05). CONCLUSION: Eliminating PORT to the PN0 neck resulted in excellent control rates in the unirradiated neck without long-term adverse effects on global QOL.
Authors: Aisling S Last; Patrik Pipkorn; Stephanie Chen; Dorina Kallogjeri; Joseph Zenga; Jason T Rich; Randal Paniello; Jose Zevallos; Rebecca Chernock; Douglas Adkins; Peter Oppelt; Hiram Gay; Mackenzie Daly; Wade Thorstad; Ryan S Jackson Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-01-01 Impact factor: 6.223
Authors: Alexander Lin; Erika S Helgeson; Nathaniel S Treister; Brian L Schmidt; Lauren L Patton; Linda S Elting; Rajesh V Lalla; Michael T Brennan; Thomas P Sollecito Journal: Oral Oncol Date: 2022-02-26 Impact factor: 5.337
Authors: Vishal R Dhere; Chase E Escott; Sibo Tian; Jeffrey M Switchenko; James P Bell; William A Stokes; Mark W McDonald; Kelly R Magliocca; Brian J Boyce; Azeem S Kaka; Conor E Steuer; Nabil F Saba; Dong M Shin; Canhua Xiao; Mihir R Patel; Jonathan J Beitler Journal: Head Neck Date: 2021-12-01 Impact factor: 3.147
Authors: Nicolette Taku; Gregory Chronowski; G Brandon Gunn; William H Morrison; Neil D Gross; Amy C Moreno; Renata Ferrarotto; Steven J Frank; C David Fuller; Ryan P Goepfert; Jack Phan; Stephen Y Lai; Jay P Reddy; David I Rosenthal; Adam S Garden Journal: Int J Radiat Oncol Biol Phys Date: 2022-05-02 Impact factor: 8.013
Authors: Olgun Elicin; Paul Martin Putora; Marco Siano; Martina A Broglie; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Pavel Dulguerov; Guido Henke Journal: Front Oncol Date: 2019-10-24 Impact factor: 6.244
Authors: D Strüder; S Hellwig; H Rennau; S van Bonn; S P Schraven; R Mlynski; G Hildebrandt; T Schuldt Journal: Eur Arch Otorhinolaryngol Date: 2020-09-01 Impact factor: 2.503
Authors: Pencilla Lang; Jessika Contreras; Noah Kalman; Claire Paterson; Houda Bahig; Astrid Billfalk-Kelly; Sinead Brennan; Kathy Rock; Nancy Read; Varagur Venkatesan; Jinka Sathya; Lucas C Mendez; S Danielle MacNeil; Anthony C Nichols; Kevin Fung; Adrian Mendez; Eric Winquist; Sara Kuruvilla; Paul Stewart; Andrew Warner; Sylvia Mitchell; Julie A Theurer; David A Palma Journal: Radiat Oncol Date: 2020-08-14 Impact factor: 3.481